Dabigatran ( DrugBank: Dabigatran )


5 diseases
IDDisease name (Link within this page)Number of trials
51Scleroderma1
75Cushing disease1
85Idiopathic interstitial pneumonia1
91Budd-Chiari syndrome1
124Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy1

51. Scleroderma


Clinical trials : 525Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

75. Cushing disease


Clinical trials : 205Drugs : 176 - (DrugBank : 45) / Drug target genes : 61 - Drug target pathways : 127 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

85. Idiopathic interstitial pneumonia


Clinical trials : 627Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

91. Budd-Chiari syndrome


Clinical trials : 4Drugs : 5 - (DrugBank : 4) / Drug target genes : 4 - Drug target pathways : 14 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy


Clinical trials : 12Drugs : 14 - (DrugBank : 5) / Drug target genes : 3 - Drug target pathways : 11 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries